Last reviewed · How we verify
Pred + Meth
A combination of prednisolone (a corticosteroid) and methotrexate (an immunosuppressant/antimetabolite) that suppresses inflammation and immune activity.
A combination of prednisolone (a corticosteroid) and methotrexate (an immunosuppressant/antimetabolite) that suppresses inflammation and immune activity. Used for Autoimmune and inflammatory disorders (specific indication not publicly detailed for this Phase 3 trial).
At a glance
| Generic name | Pred + Meth |
|---|---|
| Also known as | Prednisolone, Methotrexate |
| Sponsor | Hamad Medical Corporation |
| Drug class | Corticosteroid + Antimetabolite combination |
| Target | Glucocorticoid receptor (prednisolone); Dihydrofolate reductase (methotrexate) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Prednisolone reduces inflammation by suppressing immune cell activation and cytokine production. Methotrexate inhibits dihydrofolate reductase and has immunosuppressive effects through multiple pathways including adenosine release. Together, they provide synergistic anti-inflammatory and immunosuppressive effects for autoimmune and inflammatory conditions.
Approved indications
- Autoimmune and inflammatory disorders (specific indication not publicly detailed for this Phase 3 trial)
Common side effects
- Infection
- Bone marrow suppression
- Gastrointestinal disturbance
- Hepatotoxicity
- Immunosuppression-related complications
Key clinical trials
- Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pred + Meth CI brief — competitive landscape report
- Pred + Meth updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI